Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Ltd’s shares touched a new 52-week low of Rs.0.54 today, marking a significant decline amid ongoing financial pressures and subdued market sentiment within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week and all-time low price of Rs.0.54, marking a significant decline in its stock value over the past year.

Shree Ganesh Biotech India Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new all-time low of Rs.0.54, marking a significant milestone in its ongoing downward trajectory. The stock’s recent performance highlights persistent difficulties reflected in its financial and market metrics.

Shree Ganesh Biotech India Ltd’s stock has declined to an all-time low, closing just 3.51% above its 52-week low of Rs 0.55 on 16 Mar 2026. The micro-cap pharmaceutical and biotechnology company continues to face significant headwinds, reflected in its deteriorating financial metrics and sustained negative returns over multiple time horizons.

Shree Ganesh Biotech India Ltd has touched a new 52-week and all-time low of Rs.0.55, marking a significant decline in its stock price amid broader market pressures and company-specific financial concerns.

Shares of Shree Ganesh Biotech India Ltd have declined to an all-time low, reflecting a sustained period of underperformance within the Pharmaceuticals & Biotechnology sector. The stock closed just 1.75% above its 52-week low of Rs 0.56, marking a significant milestone in its downward trajectory amid broader market pressures and company-specific financial strains.

Shree Ganesh Biotech India Ltd has touched a new 52-week and all-time low of Rs.0.56 today, marking a significant decline in its stock price amid broader market pressures and company-specific financial concerns.

Shree Ganesh Biotech India Ltd’s stock plunged to a new all-time low of Rs.0.58 on 9 Mar 2026, marking a significant milestone in its ongoing decline. The pharmaceutical and biotechnology company’s shares have underperformed across multiple time frames, reflecting persistent financial and market pressures.

Shree Ganesh Biotech India Ltd has reached an all-time low, closing just 3.33% above its 52-week low of ₹0.58, marking a significant milestone in its ongoing decline. The stock’s performance continues to lag behind key benchmarks, reflecting persistent difficulties within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Shree Ganesh Biotech India Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a pause in its previously negative trend. Despite a modest improvement in profitability over the nine-month period, the company continues to face operational challenges, particularly in debtor management and revenue growth, which have weighed on investor sentiment and share price performance.

Shree Ganesh Biotech India Ltd. reported a net profit of just ₹0.01 crores for Q2 FY26, representing a staggering decline of 96.97% quarter-on-quarter and 96.88% year-on-year. The micro-cap pharmaceutical company, with a market capitalisation of ₹26.00 crores, continues to struggle with severe revenue contraction and mounting operational challenges. The stock has plunged 34.04% over the past year, closing at ₹0.62 on January 29, 2026, trading 46.09% below its 52-week high of ₹1.15.

Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Aug 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and prospects.

Shree Ganesh Bio, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation metrics. This shift reflects ongoing challenges in the company’s financial performance, valuation concerns, and technical indicators, underscoring the difficulties faced by the firm in the current market environment.

Shares of Shree Ganesh Biotech India have reached a new 52-week low of Rs.0.58, marking a significant decline in the stock’s valuation amid a challenging year for the company within the Pharmaceuticals & Biotechnology sector.